Search Results - "DeConti, Ronald C."

Chemotherapy of Squamous Cell Carcinoma of the Skin by DeConti, Ronald C

“…The role of systemic chemotherapy with cytotoxic agents in squamous cell carcinoma of the skin remains uncertain. A number of agents in combination have been…”
Get full text

Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma by DAUD, Adil I, DECONTI, Ronald C, HELLER, Richard, ANDREWS, Stephanie, URBAS, Patricia, RIKER, Adam I, SONDAK, Vernon K, MUNSTER, Pamela N, SULLIVAN, Daniel M, UGEN, Kenneth E, MESSINA, Jane L

“…Gene-based immunotherapy for cancer is limited by the lack of safe, efficient, reproducible, and titratable delivery methods. Direct injection of DNA into…”
Get full text

Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases by Faries, Mark B., Mozzillo, Nicola, Kashani-Sabet, Mohammed, Thompson, John F., Kelley, Mark C., DeConti, Ronald C., Lee, Jeffrey E., Huth, James F., Wagner, Jeffrey, Dalgleish, Angus, Pertschuk, Daniel, Nardo, Christopher, Stern, Stacey, Elashoff, Robert, Gammon, Guy, Morton, Donald L.

“…Background This phase III study was undertaken to evaluate the efficacy of an allogeneic whole-cell vaccine (Canvaxin™) plus bacillus Calmette-Guerin (BCG)…”
Get full text

Phenotypic and Functional Analysis of Dendritic Cells and Clinical Outcome in Patients With High-Risk Melanoma Treated With Adjuvant Granulocyte Macrophage Colony-Stimulating Factor by DAUD, Adil I, MIRZA, Noweeda, GABRILOVICH, Dmitry, LENOX, Brianna, ANDREWS, Stephanie, URBAS, Patricia, GAO, Gui X, LEE, Ji-Hyun, SONDAK, Vernon K, RIKER, Adam I, DECONTI, Ronald C

“…Granulocyte macrophage colony-stimulating factor (GM-CSF) can induce differentiation of dendritic cells (DCs) in preclinical models. We hypothesized that…”
Get full text

Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group by GIBSON, Michael K, YI LI, MURPHY, Barbara, HUSSAIN, Maha H. A, DECONTI, Ronald C, ENSLEY, John, FORASTIERE, Arlene A

“…To determine the response rate, survival and toxicity of infusional cisplatin plus fluorouracil (CF) versus cisplatin plus paclitaxel (CP) in patients with…”
Get full text

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial by DAUD, Adil I, DAWSON, Jana, MUNSTER, Pamela N, DECONTI, Ronald C, BICAKU, Elona, MARCHION, Douglas, BASTIEN, Sem, HAUSHEER, Frederick A, LUSH, Richard, NEUGER, Anthony, SULLIVAN, Daniel M

“…Purpose: The novel topoisomerase I inhibitor karenitecin (KTN) shows activity against melanoma. We examined whether histone deacetylase inhibition could…”
Get full text

Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma by MITCHELL, Malcolm S, ABRAMS, Judith, JAKOWATZ, James G, DAS GUPTA, Tapas K, RICHARDS, Jon M, SAMLOWSKI, Wolfram E, COSTANZI, John J, ARONSON, Frederick R, DEISSEROTH, Albert B, DUDEK, Arkadiusz Z, JONES, Vicky E, THOMPSON, John A, KASHANI-SABET, Mohammed, DECONTI, Ronald C, HWU, Wen-Jen, ATKINS, Michael B, WHITMAN, Eric, ERNSTOFF, Marc S, HALUSKA, Frank G

“…To compare the overall survival (OS) of patients with resected stage III melanoma administered active specific immunotherapy and low-dose interferon alfa-2b…”
Get full text

Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma by Gibney, Geoffrey T, Kudchadkar, Ragini R, DeConti, Ronald C, Thebeau, Melissa S, Czupryn, Maria P, Tetteh, Leticia, Eysmans, Cabell, Richards, Allison, Schell, Michael J, Fisher, Kate J, Horak, Christine E, Inzunza, H David, Yu, Bin, Martinez, Alberto J, Younos, Ibrahim, Weber, Jeffrey S

“…The anti-programmed death-1 (PD-1) antibody nivolumab (BMS-936558) has clinical activity in patients with metastatic melanoma. Nivolumab plus vaccine was…”
Get full text

Introduction: Advanced Cutaneous Malignancies by Glass, L. Frank, MD, DeConti, Ronald C., MD, Sondak, Vernon K., MD

Get full text

Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study by DAUD, Adil, VALKOV, Nikola, HAUSHEER, Frederick, SULLIVAN, Daniel, CENTENO, Barbara, DERDERIAN, Jennifer, SULLIVAN, Patricia, MUNSTER, Pamela, URBAS, Patricia, DECONTI, Ronald C, BERGHORN, Elmer, ZHENMEI LIU

“…Purpose: A phase II trial of the novel camptothecin karenitecin (BNP1350) was conducted to determine its efficacy and tolerability in patients with metastatic…”
Get full text

Phase III Comparison of High-Dose Paclitaxel + Cisplatin + Granulocyte Colony-Stimulating Factor Versus Low-Dose Paclitaxel + Cisplatin in Advanced Head and Neck Cancer: Eastern Cooperative Oncology Group Study E1393 by FORASTIERE, Arlene A, LEONG, Traci, ROWINSKY, Eric, MURPHY, Barbara A, VLOCK, Daniel R, DECONTI, Ronald C, ADAMS, George L

“…To determine dose-response effects and the activity of paclitaxel combined with cisplatin in patients with incurable squamous cell carcinoma of the head and…”
Get full text

Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck by Tanvetyanon, Tawee, Padhya, Tapan, McCaffrey, Judith, Kish, Julie A., Deconti, Ronald C., Trotti, Andy, Rao, Nikhil G.

“…Background Despite resection followed by adjuvant radiotherapy, high‐risk cutaneous squamous cell carcinomas of the head and neck region (SCCHN) often recur…”
Get full text

A Phase 2 Trial of Bortezomib Followed by the Addition of Doxorubicin at Progression in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck: A Trial of the Eastern Cooperative Oncology Group (E1303) by ARGIRIS, Athanassios, GHEBREMICHAEL, Musie, BURTNESS, Barbara, AXELROD, Rita S, DECONTI, Ronald C, FORASTIERE, Arlene A

“…Bortezomib, an inhibitor of the 26S proteasome and NF-κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy…”
Get full text

Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma by Smith, Franz O., Yue, Binglin, Marzban, Suroosh S., Walls, Brooke L., Carr, Michael, Jackson, Ryan S., Puleo, Christopher A., Padhya, Tapan, Cruse, C. Wayne, Gonzalez, Ricardo J., Sarnaik, Amod A., Schell, Michael J., DeConti, Ronald C., Messina, Jane L., Sondak, Vernon K., Zager, Jonathan S.

“…BACKGROUND The purposes of this study were 1) to determine the impact of primary tumor‐related factors on the prediction of the sentinel lymph node (SLN)…”
Get full text

Recent Advances in the Understanding of the Genetics, Etiology, and Treatment of Merkel Cell Carcinoma by Donepudi, Sreekanth, DeConti, Ronald C, Samlowski, Wolfram E

“…Merkel cell carcinoma (MCC) is a highly aggressive skin malignancy. The growing incidence and recognition of this cancer in elderly or immunosuppressed…”
Get full text

A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331) by Samlowski, Wolfram E, Moon, James, Tuthill, Ralph J, Heinrich, Michael C, Balzer-Haas, Naomi S, Merl, Stuart A, DeConti, Ronald C, Thompson, John A, Witter, Merle T, Flaherty, Lawrence E, Sondak, Vernon K

“…Imatinib mesylate (Gleevec) was evaluated as a treatment for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) based on the identification of…”
Get full text

Survival after surgical resection of isolated pulmonary metastases from malignant melanoma by Andrews, Stephanie, Robinson, Lary, Cantor, Alan, DeConti, Ronald C

“…The overall prognosis for patients with metastatic malignant melanoma remains poor. However, careful staging and identification of patients with limited…”
Get more information

Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy by Heller, Richard, Jaroszeski, Mark J., Glass, L. Frank, Messina, Jane L., Rapaport, David P., DeConti, Ronald C., Fenske, Neil A., Gilbert, Richard A., Mir, Lluis M., Reintgen, Douglas S.

“…BACKGROUND Electroporation is a process that causes a transient increase in the permeability of cell membranes. It can be used to increase the intracellular…”
Get full text

Phase II Evaluation of 96-Hour Paclitaxel Infusion in Advanced (Recurrent or Metastatic) Squamous Cell Carcinoma of the Head and Neck (E3395): A Trial of the Eastern Cooperative Oncology Group by Langer, Corey J., Li, Yi, Jennings, Timothy, DeConti, Ronald C., Nair, Suresh, Cohen, Roger B., Forastiere, Arlene A.

“…Background: Paclitaxel (24-hour infusion) has yielded activity in advanced squamous cell carcinoma of the head and neck (SCCHN). Protracted exposure to…”
Get full text

Chemotherapy of Squamous Cell Carcinoma of the Skin : ADVANCED CUTANEOUS MALIGNANCIES by DECONTI, Ronald C

Get full text